CD38-Directed Therapies for Management of Multiple Myeloma

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–1060. doi:10.1056/NEJMra1011442
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128. doi:10.1038/leu.2013.313
   PubMed Web of Science ®Google Scholar
• Weiner LM. Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer. Nat Rev Cancer. 2007;7(9):701–706. doi:10.1038/nrc2209
   PubMed Web of Science ®Google Scholar
• van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13–29. doi:10.1182/blood-2017-06-740944
   PubMed Web of Science ®Google Scholar
• Nakagawara K, Mori M, Takasawa S, et al. Assignment of CD38, the gene encoding human leukocyte antigen CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase), to chromosome 4p15. Cytogenet Cell Genet. 1995;69(1–2):38–39. doi:10.1159/000133933
   Google Scholar
• Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res. 2001;25(1):1–12. doi:10.1016/S0145-2126(00)00093-X
   PubMed Web of Science ®Google Scholar
• Leo R, Boeker M, Peest D, et al. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol. 1992;64(3):132–139. doi:10.1007/BF01697400
   Web of Science ®Google Scholar
• Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T. Immunotherapies targeting CD38 in multiple myeloma. Oncoimmunology. 2016;5(11):e1217374. doi:10.1080/2162402X.2016.1217374
   PubMed Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394. doi:10.1182/blood-2015-12-687749
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai Y-T, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–1848. doi:10.4049/jimmunol.1003032
   PubMed Web of Science ®Google Scholar
• Krejcik J, Frerichs KA, Nijhof IS, et al. Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab. Clin Cancer Res. 2017;23(24):7498–7511. doi:10.1158/1078-0432.CCR-17-2027
   PubMed Web of Science ®Google Scholar
• Jansen JHM, Marco jansen JH, Boross P, et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via fc receptor-mediated crosslinking. Blood. 2012;120(21):2974. doi:10.1182/blood.v120.21.2974.2974
   Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–1219. doi:10.1056/NEJMoa1506348
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–1560. doi:10.1016/S0140-6736(15)01120-4
   PubMed Web of Science ®Google Scholar
• Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a Randomized, Open-Label, Phase 3 Study. Leukemia. 2020;34(7):1875–1884. doi:10.1038/s41375-020-0711-6
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Sonneveld P, Hungria V, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020;20(8):509–518. doi:10.1016/j.clml.2019.09.623
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, San-Miguel J, Casneuf T, et al. Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39(10):JCO2001814. doi:10.1200/JCO.20.01814
   Web of Science ®Google Scholar
• Dimopoulos M, Quach H, Mateos M-V, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186–197. doi:10.1016/S0140-6736(20)30734-0
   PubMed Web of Science ®Google Scholar
• Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130(8):974–981. doi:10.1182/blood-2017-05-785246
   PubMed Web of Science ®Google Scholar
• Siegel DS, Schiller GJ, Samaras C, et al. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Leukemia. 2020;34(12):3286–3297. doi:10.1038/s41375-020-0813-1
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E, Boccadoro M, et al. Apollo: phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) alone in patients (Pts) with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Supplement 1):5–6. doi:10.1182/blood-2020-135874
   Web of Science ®Google Scholar
• Mateos M-V, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. Transfus Cell Ther. 2018;378(6):518–528. doi:10.1056/nejmoa1714678
   Google Scholar
• Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–2115. doi:10.1056/nejmoa1817249
   PubMed Web of Science ®Google Scholar
• Roussel M, Moreau P, Hebraud B, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. Lancet Haematol. 2020;7(12):e874–e883. doi:10.1016/S2352-3026(20)30356-2
   Web of Science ®Google Scholar
• Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936–945. doi:10.1182/blood.2020005288
   PubMed Web of Science ®Google Scholar
• Landgren O, Hultcrantz M, Lesokhin AM, et al. Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: a Clinical and Correlative Phase 2 Study. Blood. 2019;134(Supplement_1):862. doi:10.1182/blood-2019-126378
   Web of Science ®Google Scholar
• Costa LJ, Chhabra S, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based dara-krd consolidation in patients with newly diagnosed multiple myeloma (NDMM). Blood. 2019;134(11):860. doi:10.1182/blood-2019-123170
   Web of Science ®Google Scholar
• Deckert J, Wetzel M-C, Bartle LM, et al. SAR650984, A novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38 +hematologic malignancies. Clin Cancer Res. 2014;20(17):4574–4583. doi:10.1158/1078-0432.ccr-14-0695
   PubMed Web of Science ®Google Scholar
• Feng X, Zhang L, Acharya C, et al. Targeting CD38 suppresses induction and function of t regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23(15):4290–4300. doi:10.1158/1078-0432.ccr-16-3192
   PubMed Web of Science ®Google Scholar
• Moreno L, Perez C, Zabaleta A, et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019;25(10):3176–3187. doi:10.1158/1078-0432.ccr-18-1597
   PubMed Web of Science ®Google Scholar
• Martin T, Strickland S, Glenn M, et al. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer J. 2019;9(4):41. doi:10.1038/s41408-019-0198-4
   PubMed Web of Science ®Google Scholar
• Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;129(25):3294–3303. doi:10.1182/blood-2016-09-740787
   PubMed Web of Science ®Google Scholar
• Mikhael J, Richardson P, Usmani SZ, et al. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood. 2019;134(2):123–133. doi:10.1182/blood-2019-02-895193
   PubMed Web of Science ®Google Scholar
• Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096–2107. doi:10.1016/S0140-6736(19)32556-5
   PubMed Web of Science ®Google Scholar
• Maiolino A, Moreau P, Dimopoulos M, et al. Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (IKEMA): interim analysis of a phase 3, Randomized, Open-Label Study. Hematol Transfus Cell Ther. 2020;42:262–263. doi:10.1016/j.htct.2020.10.439
   Google Scholar
• Mikhael J, Belhadj-Merzoug K, Hulin C, et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021;11(89). doi:10.1038/s41408-021-00478-4
   Web of Science ®Google Scholar
• Moreau P, van de Donk NWCJ, Miguel JS, et al. Practical considerations for the use of daratumumab, a novel CD38 monoclonal antibody, in myeloma. Drugs. 2016;76(8):853–867. doi:10.1007/s40265-016-0573-4
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Nahi H, Mateos MV, van de Donk N, Chari A. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood. 2019;134(8):668–677. doi:10.1182/blood.2019000667
   PubMed Web of Science ®Google Scholar
• van de Donk NWCJ, Otten HG, El Haddad O. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin Chem Lab Med. 2016;54(6):1105–1109. PMID: 26812873. doi:10.1515/cclm-2015-0888.
   PubMed Web of Science ®Google Scholar
• Oostendorp M, Lammerts van Bueren JJ, Doshi P. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015;55(6 Pt 2):1555–1562. Epub 2015 May 18. PMID: 25988285. doi:10.1111/trf.13150
   PubMed Web of Science ®Google Scholar
• Tolcher AW. Antibody drug conjugates: lessons from 20 years of clinical experience. Ann Oncol. 2016;27(12):2168–2172. doi:10.1093/annonc/mdw424
   PubMed Web of Science ®Google Scholar
• Nittoli T, Kelly MP, Delfino F, et al. Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids. Bioorg Med Chem. 2018;26(9):2271–2279. doi:10.1016/j.bmc.2018.02.025
   Web of Science ®Google Scholar
• Peters C, Brown S. Antibody–drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4). doi:10.1042/bsr20150089
   Web of Science ®Google Scholar
• Goldmacher VS, Bourret LA, Levine BA, et al. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood. 1994;84(9):3017–3025. doi:10.1182/blood.V84.9.3017.3017
   PubMed Web of Science ®Google Scholar
• Bolognesi A, Polito L, Farini V, et al. CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia. J Biol Regul Homeost Agents. 2005;19(3–4):145–152.
   PubMed Web of Science ®Google Scholar
• Green DJ, Orgun NN, Jones JC, et al. A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. Cancer Res. 2014;74(4):1179–1189. doi:10.1158/0008-5472.CAN-13-1589
   Web of Science ®Google Scholar
• Green DJ, Orgun NN, Hylarides MD, et al. Anti-CD38 pretargeted radioimmunotherapy demonstrates therapeutic efficacy in a human multiple myeloma mouse xenograft model. Blood. 2011;118(21):1842. doi:10.1182/blood.v118.21.1842.1842
   Web of Science ®Google Scholar
• Li T, Qi S, Unger M, et al. Immuno-targeting the multifunctional CD38 using nanobody. Sci Rep. 2016;6(1):27055. doi:10.1038/srep27055
   Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847. doi:10.1056/NEJMoa1609783
   PubMed Web of Science ®Google Scholar
• Richter JR, Landgren CO, Kauh JS, et al. Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/ refractory multiple myeloma. J Clin Oncol. 2018;36(15_suppl):TPS3132–TPS3132. doi:10.1200/jco.2018.36.15_suppl.tps3132
   Web of Science ®Google Scholar
• Chu SY, Miranda Y, Phung S, et al. Immunotherapy with long-lived anti-CD38 × anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human myeloma cell lines and CD38 cells in monkeys: a potential therapy for multiple myeloma. Blood. 2014;124(21):4727. doi:10.1182/blood.v124.21.4727.4727
   Web of Science ®Google Scholar
• Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation. 1990;49(4):697–702. doi:10.1097/00007890-199004000-00009
   PubMed Web of Science ®Google Scholar
• Wang L, Hoseini SS, Xu H, Ponomarev V, Cheung N-K. Silencing Fc domains in T cell–engaging bispecific antibodies improves T-cell trafficking and antitumor potency. Cancer Immunol Res. 2019;7(12):2013–2024. doi:10.1158/2326-6066.cir-19-0121
   PubMed Web of Science ®Google Scholar
• June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73. doi:10.1056/NEJMra1706169
   PubMed Web of Science ®Google Scholar
• Drent E, Themeli M, Poels R, et al. A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Mol Ther. 2017;25(8):1946–1958. doi:10.1016/j.ymthe.2017.04.024
   PubMed Web of Science ®Google Scholar
• Drent E, Groen RWJ, Noort WA, Themeli M, van Bueren JJL. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica. 2016;101(5):616–625. doi:10.3324/haematol.2015.137620
   PubMed Web of Science ®Google Scholar
• Drent E, Poels R, Mulders MJ, et al. Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design. PLoS One. 2018;13(5):e0197349. doi:10.1371/journal.pone.0197349
   PubMed Web of Science ®Google Scholar
• Van de Donk NWCJ, Usmani SZ. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol. 2018;9:2134. doi:10.3389/fimmu.2018.02134
   PubMed Web of Science ®Google Scholar